MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer

Madelon J H Metman; Pascal K C Jonker; Luc H J Sondorp; Bettien M van Hemel; Mark S Sywak; Anthony J Gill; Liesbeth Jansen; Paul J van Diest; Tessa M van Ginhoven; Clemens W G M Löwik; Anh H Nguyen; Dominic J Robinson; Gooitzen M van Dam; Thera P Links; Rob P Coppes; Rudolf S N Fehrmann; Schelto Kruijff

doi:10.1007/s00259-023-06525-5

MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer

Madelon J H Metman, Pascal K C Jonker, Luc H J Sondorp, Bettien M van Hemel, Mark S Sywak, Anthony J Gill, Liesbeth Jansen, Paul J van Diest, Tessa M van Ginhoven, Clemens W G M Löwik, Anh H Nguyen, Dominic J Robinson, Gooitzen M van Dam, Thera P Links, Rob P Coppes, Rudolf S N Fehrmann, Schelto Kruijff^*

^*Corresponding author voor dit werk

Onderzoeksoutput › Academic › peer review

4 Citaten (Scopus)

9 Downloads (Pure)

Samenvatting

PURPOSE: Multifocal disease in PTC is associated with an increased recurrence rate. Multifocal disease (MD) is underdiagnosed with the current gold standard of pre-operative ultrasound staging. Here, we evaluate the use of EMI-137 targeted molecular fluorescence-guided imaging (MFGI) and spectroscopy as a tool for the intra-operative detection of uni- and multifocal papillary thyroid cancer (PTC) aiming to improve disease staging and treatment selection.

METHODS: A phase-1 study (NCT03470259) with EMI-137 was conducted to evaluate the possibility of detecting PTC using MFGI and quantitative fiber-optic spectroscopy.

RESULTS: Fourteen patients underwent hemi- or total thyroidectomy (TTX) after administration of 0.09 mg/kg (n = 1), 0.13 mg/kg (n = 8), or 0.18 mg/kg (n = 5) EMI-137. Both MFGI and spectroscopy could differentiate PTC from healthy thyroid tissue after administration of EMI-137, which binds selectively to MET in PTC. 0.13 mg/kg was the lowest dosage EMI-137 that allowed for differentiation between PTC and healthy thyroid tissue. The smallest PTC focus detected by MFGI was 1.4 mm. MFGI restaged 80% of patients from unifocal to multifocal PTC compared to ultrasound.

CONCLUSION: EMI-137-guided MFGI and spectroscopy can be used to detect multifocal PTC. This may improve disease staging and treatment selection between hemi- and total thyroidectomy by better differentiation between unifocal and multifocal disease.

TRIAL REGISTRATION: NCT03470259.

Originele taal-2	English
Pagina's (van-tot)	2384–2394
Aantal pagina's	11
Tijdschrift	European Journal of Nuclear Medicine and Molecular Imaging
Volume	51
Vroegere onlinedatum	29-nov.-2023
DOI's	https://doi.org/10.1007/s00259-023-06525-5
Status	Published - jul.-2024

Toegang tot document

10.1007/s00259-023-06525-5Licentie: CC BY

MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancerFinal publisher's version, 2,17 MBLicentie: CC BY

Handle.net

Permanente koppeling

Citeer dit

Metman, M. J. H., Jonker, P. K. C., Sondorp, L. H. J., van Hemel, B. M., Sywak, M. S., Gill, A. J., Jansen, L., van Diest, P. J., van Ginhoven, T. M., Löwik, C. W. G. M., Nguyen, A. H., Robinson, D. J., van Dam, G. M., Links, T. P., Coppes, R. P., Fehrmann, R. S. N., & Kruijff, S. (2024). MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 51, 2384–2394. https://doi.org/10.1007/s00259-023-06525-5

@article{9ce53b460a024159a3ccba2568bd36e9,

title = "MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer",

abstract = "PURPOSE: Multifocal disease in PTC is associated with an increased recurrence rate. Multifocal disease (MD) is underdiagnosed with the current gold standard of pre-operative ultrasound staging. Here, we evaluate the use of EMI-137 targeted molecular fluorescence-guided imaging (MFGI) and spectroscopy as a tool for the intra-operative detection of uni- and multifocal papillary thyroid cancer (PTC) aiming to improve disease staging and treatment selection.METHODS: A phase-1 study (NCT03470259) with EMI-137 was conducted to evaluate the possibility of detecting PTC using MFGI and quantitative fiber-optic spectroscopy.RESULTS: Fourteen patients underwent hemi- or total thyroidectomy (TTX) after administration of 0.09 mg/kg (n = 1), 0.13 mg/kg (n = 8), or 0.18 mg/kg (n = 5) EMI-137. Both MFGI and spectroscopy could differentiate PTC from healthy thyroid tissue after administration of EMI-137, which binds selectively to MET in PTC. 0.13 mg/kg was the lowest dosage EMI-137 that allowed for differentiation between PTC and healthy thyroid tissue. The smallest PTC focus detected by MFGI was 1.4 mm. MFGI restaged 80% of patients from unifocal to multifocal PTC compared to ultrasound.CONCLUSION: EMI-137-guided MFGI and spectroscopy can be used to detect multifocal PTC. This may improve disease staging and treatment selection between hemi- and total thyroidectomy by better differentiation between unifocal and multifocal disease.TRIAL REGISTRATION: NCT03470259.",

author = "Metman, {Madelon J H} and Jonker, {Pascal K C} and Sondorp, {Luc H J} and {van Hemel}, {Bettien M} and Sywak, {Mark S} and Gill, {Anthony J} and Liesbeth Jansen and {van Diest}, {Paul J} and {van Ginhoven}, {Tessa M} and L{\"o}wik, {Clemens W G M} and Nguyen, {Anh H} and Robinson, {Dominic J} and {van Dam}, {Gooitzen M} and Links, {Thera P} and Coppes, {Rob P} and Fehrmann, {Rudolf S N} and Schelto Kruijff",

note = "{\textcopyright} 2023. The Author(s).",

year = "2024",

month = jul,

doi = "10.1007/s00259-023-06525-5",

language = "English",

volume = "51",

pages = "2384–2394",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer",

}

Metman, MJH , Jonker, PKC , Sondorp, LHJ , van Hemel, BM, Sywak, MS, Gill, AJ, Jansen, L, van Diest, PJ, van Ginhoven, TM, Löwik, CWGM, Nguyen, AH, Robinson, DJ, van Dam, GM , Links, TP , Coppes, RP , Fehrmann, RSN & Kruijff, S 2024, 'MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer', European Journal of Nuclear Medicine and Molecular Imaging, vol. 51, blz. 2384–2394. https://doi.org/10.1007/s00259-023-06525-5

TY - JOUR

T1 - MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer

AU - Metman, Madelon J H

AU - Jonker, Pascal K C

AU - Sondorp, Luc H J

AU - van Hemel, Bettien M

AU - Sywak, Mark S

AU - Gill, Anthony J

AU - Jansen, Liesbeth

AU - van Diest, Paul J

AU - van Ginhoven, Tessa M

AU - Löwik, Clemens W G M

AU - Nguyen, Anh H

AU - Robinson, Dominic J

AU - van Dam, Gooitzen M

AU - Links, Thera P

AU - Coppes, Rob P

AU - Fehrmann, Rudolf S N

AU - Kruijff, Schelto

PY - 2024/7

Y1 - 2024/7

N2 - PURPOSE: Multifocal disease in PTC is associated with an increased recurrence rate. Multifocal disease (MD) is underdiagnosed with the current gold standard of pre-operative ultrasound staging. Here, we evaluate the use of EMI-137 targeted molecular fluorescence-guided imaging (MFGI) and spectroscopy as a tool for the intra-operative detection of uni- and multifocal papillary thyroid cancer (PTC) aiming to improve disease staging and treatment selection.METHODS: A phase-1 study (NCT03470259) with EMI-137 was conducted to evaluate the possibility of detecting PTC using MFGI and quantitative fiber-optic spectroscopy.RESULTS: Fourteen patients underwent hemi- or total thyroidectomy (TTX) after administration of 0.09 mg/kg (n = 1), 0.13 mg/kg (n = 8), or 0.18 mg/kg (n = 5) EMI-137. Both MFGI and spectroscopy could differentiate PTC from healthy thyroid tissue after administration of EMI-137, which binds selectively to MET in PTC. 0.13 mg/kg was the lowest dosage EMI-137 that allowed for differentiation between PTC and healthy thyroid tissue. The smallest PTC focus detected by MFGI was 1.4 mm. MFGI restaged 80% of patients from unifocal to multifocal PTC compared to ultrasound.CONCLUSION: EMI-137-guided MFGI and spectroscopy can be used to detect multifocal PTC. This may improve disease staging and treatment selection between hemi- and total thyroidectomy by better differentiation between unifocal and multifocal disease.TRIAL REGISTRATION: NCT03470259.

AB - PURPOSE: Multifocal disease in PTC is associated with an increased recurrence rate. Multifocal disease (MD) is underdiagnosed with the current gold standard of pre-operative ultrasound staging. Here, we evaluate the use of EMI-137 targeted molecular fluorescence-guided imaging (MFGI) and spectroscopy as a tool for the intra-operative detection of uni- and multifocal papillary thyroid cancer (PTC) aiming to improve disease staging and treatment selection.METHODS: A phase-1 study (NCT03470259) with EMI-137 was conducted to evaluate the possibility of detecting PTC using MFGI and quantitative fiber-optic spectroscopy.RESULTS: Fourteen patients underwent hemi- or total thyroidectomy (TTX) after administration of 0.09 mg/kg (n = 1), 0.13 mg/kg (n = 8), or 0.18 mg/kg (n = 5) EMI-137. Both MFGI and spectroscopy could differentiate PTC from healthy thyroid tissue after administration of EMI-137, which binds selectively to MET in PTC. 0.13 mg/kg was the lowest dosage EMI-137 that allowed for differentiation between PTC and healthy thyroid tissue. The smallest PTC focus detected by MFGI was 1.4 mm. MFGI restaged 80% of patients from unifocal to multifocal PTC compared to ultrasound.CONCLUSION: EMI-137-guided MFGI and spectroscopy can be used to detect multifocal PTC. This may improve disease staging and treatment selection between hemi- and total thyroidectomy by better differentiation between unifocal and multifocal disease.TRIAL REGISTRATION: NCT03470259.

U2 - 10.1007/s00259-023-06525-5

DO - 10.1007/s00259-023-06525-5

M3 - Article

C2 - 38017325

SN - 1619-7070

VL - 51

SP - 2384

EP - 2394

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

ER -

MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit